Pelago Bioscience AB

Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics. Today, we deliver in situ target engagement studies to accelerate preclinical and clinical drug discovery and development to a world-wide customer base. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects. Our scientific team are the experts in both targeted CETSA® using antibodies for the detection and proteome-wide mass spectrometry-based CETSA® applications, find out more on the Pelago services page

The Cellular Thermal Shift Assay (CETSA®) is an easy and proven method to demonstrate ligand-protein interactions in living cells and can be used without the need of any modifications to the ligand or protein. Quantification methods like PerkinElmer’s no-wash immunoassays Alpha or Homogenous Time Resolved Fluorescence (HTRF) can be subsequently applied to confirm biologically relevant findings.

Joe Shaw, Associated Principle Scientist at AstraZeneca, will present several case studies detailing how CETSA® technology has been implemented and utilised in drug discovery projects at AstraZeneca.

Following the presentation, there will be a panel of pharma thought leaders discussing CETSA® technology. Dr Ken Comess from Abbvie, Dr Joseph Shaw from AstraZeneca and Ruth Sommerse from Pfizer will come together and explore the impact of CETSA® NAVIGATE HT in drug discovery.